Please login to the form below

Not currently logged in
Email:
Password:

vinflunine

This page shows the latest vinflunine news and features for those working in and with pharma, biotech and healthcare.

Keytruda, Opdivo narrow Tecentriq's lead in bladder cancer

Keytruda, Opdivo narrow Tecentriq's lead in bladder cancer

The trial compared Keytruda to the investigator's choice of chemotherapy agents - paclitaxel, docetaxel or vinflunine - and showed that Merck's drug improved both progression-free survival (PFS) and overall survival.

Latest news

  • NICE rejects Pierre Fabre's bladder cancer drug Javlor NICE rejects Pierre Fabre's bladder cancer drug Javlor

    NICE has handed Pierre Fabre a final draft rejection for its bladder cancer drug Javlor (vinflunine) after deciding the pharma company had failed to prove the drug's efficacy. ... This forced the NICE's appraisal committee to reconsider its initial draft

  • BMS abandons Pierre Fabre bladder cancer drug

    BMS abandons Pierre Fabre bladder cancer drug. BMS and Pierre Fabre Medicament terminate their license agreement for the development of metastatic bladder cancer chemotherapy agent, vinflunine. ... US-based Bristol-Myers Squibb and France-headquartered

  • Sanofi-aventis and BMS move closer toward merger

    BMS' oncology portfolio is also set to expand, with three oncology drug launches over the next two years: BMS 247550 (ixabepilone), MDX-010 (ipilimumab) and Javlor (vinflunine).

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics